Sido Muncul, ID1000130305

Sido Muncul stock in focus after Q3 revenue, profit rebound

Published on 11/18/2026 at 02:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sido Muncul stock is in focus after a third-quarter recovery in revenue and net income. Full-year guidance remains cautious as nine-month results lagged.

Q3 recovery meets cautious guidance

  • Third-quarter revenue rose year over year and quarter over quarter as new products and distribution channels contributed.
  • Nine-month revenue, net income and EBITDA remained below the prior-year levels.
  • Management continues to expect lower revenue and profit for 2026.
Sido Muncul, ID1000130305, Illustration mit AI erstellt.

On Tuesday, November 17, Investor.id reported a marked improvement in Sido Muncul's third-quarter performance. The Indonesian herbal medicine and pharmaceutical company generated IDR 1.03 trillion in revenue, up 14.7 percent from a year earlier and 25 percent from the previous quarter.

Third-quarter profitability rebounds

Net income attributable to owners reached IDR 285 billion, increasing 30.9 percent year over year and 53.1 percent quarter over quarter. EBITDA rose 27.5 percent year over year to IDR 395 billion, pointing to stronger operating leverage alongside the sales recovery.

The quarterly rebound has not erased the weaker first half. Revenue for the first nine months of 2026 stood at IDR 2.5 trillion, down 8.4 percent from the prior-year period. Net income declined 24.4 percent to IDR 619 billion, while EBITDA fell 21.3 percent to IDR 875 billion.

New products support recovery

Mirae Asset Sekuritas Indonesia analyst Andreas Saragih said the nine-month figures reached 70 percent of the brokerage's 2026 revenue forecast, 76 percent of its net-income forecast and 75 percent of its EBITDA forecast. Investor.id linked the improvement to inventory normalization between February and May, new products and new distribution channels.

Sales from new products and channels grew about 7 percent during the nine-month period, while older products declined 15 percent year over year. Management has also tightened monitoring of distributor and store inventories to limit a repeat of excessive stock accumulation.

Full-year outlook stays cautious

Management continues to expect 2026 revenue to decline 10 percent and profit to fall 24 percent. The 2027 targets are still being prepared and will reflect the recovery of herbal products, growth in food and beverages, product innovation and exports.

Sido Muncul's business profile

Sido Muncul is based in Indonesia and develops and manufactures herbal medicines, traditional jamu, powdered drinks, ready-to-drink beverages, supplements and pharmaceutical products. Its operations include extraction, modern herbal medicine, jamu, beverage, supplement and pharmaceutical production facilities. The company is a specialist in Indonesian herbal and wellness products, while Kalbe Farma and Tempo Scan Pacific are broader Indonesian healthcare and consumer-health peers.

Sido Muncul company details

  • Company: PT Industri Jamu dan Farmasi Sido Muncul Tbk
  • ISIN: ID1000130305
  • Business: Herbal medicine, jamu, beverages, supplements and pharmaceuticals
  • Investor relations: Sido Muncul investor relations

The Indonesian market backdrop can be followed through current market reports.

More news and analyses on Sido Muncul stock are available here.

Disclaimer...
en | ID1000130305 | SIDO MUNCUL | boerse | 70529109 | bgmi